Granulocytes cause some of the pathophysiological effects associated with the capillary no-reflow phenomenon during ischemia and in ischemia-reperfusion injury. However, no study has examined the consequences of in vivo granulocyte activation during normal perfusion pressures. In this study, we examined the effects of intracoronary administration of the complement component C5a, which is known to be a potent granulocyte activating factor. Nine open-chest, anesthetized pigs were instrumented to monitor regional coronary blood flow and segment shortening, left ventricular dP/dt, heart rate, and pulmonary artery and aortic blood pressures and to sample arterial and regional coronary venous blood for oxygen content and complete blood counts. Intracoronary infusion of human or porcine C5a in doses ranging from 10 to 500 ng produced a significant reduction in regional coronary blood flow and myocardial function. Although perfusion pressure and heart rate remained constant, venous oxygen content fell, indicating an imbalance between myocardial oxygen supply and demand. In addition, the arteriovenous difference of white blood cells was increased significantly after anaphylatoxin infusion, indicating intravascular trapping in the myocardium. Granulocytes accounted entirely for the differences in leukocyte counts because no significant changes in platelet, lymphocyte, or hematocrit levels were observed. Injection of vehicle alone did not alter any of the monitored variables. Serial sampling indicated that granulocyte extraction was increased before the reductions in coronary blood flow and myocardial function and that all effects of C5a had resolved within 2 minutes of injection. In separate studies, we examined the effects of C5a on isolated epicardial coronary arteries (750-1,000 fim diameter) of pigs. There was no vasoconstriction after exposure to C5a in buffer or in whole blood. These studies indicate that, in the presence of normal perfusion pressures, C5a activation of granulocytes results in intravascular trapping in the myocardium. Furthermore, coronary blood flow is decreased to the extent that an imbalance between myocardial oxygen supply and demand occurs, resulting in impairment of myocardial function. (Circulation Research 1988:63:483-491)
chemotactic for porcine granulocytes. 2 -5 In addition, these factors have been shown to constrict guinea pig ileum and rabbit vascular strips in vitro. 6 -9 The influence of C5a on granulocytes is of particular interest in light of recent evidence indicating that granulocytes contribute to changes in blood flow during ischemia and to the capillary no-reflow phenomenon. 10 -13 Capillary no-reflow is one component of the general no-reflow phenomenon, originally described by Majno et al 14 in brain and Krug et al 13 in heart. Activation of granulocytes may be an important mechanism underlying the stunned myocardium. 15 Supporting evidence for a role of leukocytes in disturbances of the microcirculation includes the following: 1) granulocytes can adhere to vascular endothelium 16 -18 ; 2) infusion of leukocytes causes a substantial increase in the vascular resistance of the microcirculation of skeletal muscle 19 ; 3) granulocyte depletion during myocardial ischemia reduces microvascular resistance, edema, and arrhythmias 11 ; 4) intravital microscopy in heart muscle has shown mechanical obstruction of capillaries by granulocytes 12 ; 5) granulocytes cause a capillary noreflow phenomenon after myocardial ischemia and reperfusion 20 ; and 6) granulocytes can produce superoxides and initiate oxygen free-radical injury in the myocardium. 21 ' 22 Although myocardial ischemia activates the complement cascade and promotes localization of Clq and C3 to regions of ischemia, 1 • 2324 there is no information on the effect of C5a on granulocyte trapping in the coronary circulation, on coronary blood flow, or on myocardial function in the normal heart in vivo subjected to normal perfusion pressures. One in vitro study using guinea pig hearts perfused with Ringer's solution demonstrated that C3a caused vasoconstriction and a reduction in left ventricular contractile force. 25 Therefore, we proposed that injection of C5a would activate granulocytes and cause them to be trapped in the coronary circulation and that this effect would be closely associated in time with a reduction in coronary blood flow and myocardial function. If administration of C5a resulted in granulocyte trapping and subsequent myocardial ischemia, the ischemia would be a consequence of the C5a administration, rather than the initiating factor.
Materials and Methods

Surgical Preparation
Ten adult domestic pigs of either sex, weighing between 40 and 55 kg, were preanesthetized with ketamine (20 mg/kg i.m.) and atropine sulphate (0.04 mg/kg i.m.). Sodium thiamylal (20 mg/kg) was then injected into a marginal ear vein, and a tracheotomy was performed to allow positive pressure ventilation. The femoral artery and vein on one side were cannulated for blood sampling and infusions, respectively. Arterial blood gases were measured frequently (ABL3 Radiometer, Copenhagen, Denmark) and were maintained within physiological limits by adjusting the respirator, by administering supplemental oxygen, and by infusion of sodium bicarbonate (150 mM i.v.). Anesthesia was maintained by administration of a-chloralose (100 mg/kg i.v., initial bolus; 25 mg/kg every 30 minutes).
Both carotid arteries were cannulated, one for recording proximal aortic pressure, and one for placement of a catheter-tipped left ventricular pressure transducer (Millar Instruments, Houston, Texas). The chest was opened by midline sternotomy, and the heart was suspended in a pericardial cradle. During manipulation of the heart, a lidocaine drip (2 mg/min i.v.) was used to limit arrhythmias. The lidocaine drip was stopped in several animals after instrumentation without evidence of arrhythmias. A pulmonary artery cannula was inserted for measurement of pulmonary arterial blood pressure. The left anterior descending coronary artery (LAD) was dissected proximal to its first diagonal branch for placement of an electromagnetic flow transducer (Biotronix, Silver Spring, Maryland). The anterior cardiac vein adjacent to the proximal LAD also was dissected free from the surrounding myocardium.
Two pairs of ultrasonic dimension crystals (2 mm diameter) were positioned, one in posterior myocardium in the region supplied by the circumflex coronary artery (LCX) and the other in the anterior myocardium in the region supplied by the LAD, for measurement of local segment function. 26 Care was taken to place the crystals in the midmyocardium, along the circumferential or hoop axis. Their positions were confirmed during postmortem surgery.
An intra-arterial catheter was placed proximal to the flow transducer on the LAD as described previously. 27 At this time, the animals received heparin (750 units/kg, initial bolus; 250 units/kg hourly thereafter). The cardiac vein was ligated and cannulated so that the cannula tip was positioned adjacent to the arterial catheter. An extension tubing was attached to the venous catheter, and the outflow was directed into a reservoir. Samples of regional coronary venous blood were collected by attaching syringes to this extension tubing. Venous blood was returned continuously to the animal except during, and for 2 minutes after, the C5a injections. In this manner, the systemic circulatory effects of C5a were minimized. Intravenous fluid or donor blood was given to maintain the animal's circulating volume.
Arterial blood pressure, left ventricular pressure and dP/dt, instantaneous heart rate, coronary blood flow (LAD), segment function (LAD or anterior and LCX or posterior), and pulmonary artery pressure were recorded continuously (Mingograf, SiemensElema, Sweden). Heart rate and dP/dt were derived from the left ventricular pressure signal. The electromagnetic flow transducer signal was calibrated at zero and balanced regularly throughout the study by temporarily occluding the LAD just distal to the transducer. At the end of each procedure, the flowmeter was calibrated with the animal's blood. Fractional shortening of each region was calculated [(end-diastolic length -end-systolic length)/enddiastolic length] x 100% as an estimate of segment function. End-diastolic length was measured at the point of the initial upsweep of the left ventricular pressure signal or R wave on an electrocardiogram. End-systolic length was measured 20 msec before peak negative dP/dt. Three cardiac cycles recorded with respiration stopped at end expiration were averaged for calculation of fractional shortening. Total coronary vascular resistance in the LAD region was estimated as the ratio of mean aortic pressure to coronary blood flow.
Experimental Protocols
After instrumentation was complete, the animals were allowed to stabilize for at least 30 minutes.
Blood samples were withdrawn simultaneously from the systemic artery and coronary vein for measurement of blood gases and blood counts (hematocrit, platelet, granulocyte, lymphocyte levels). Then, in random fashion, 1 ml of either the C5a or vehicle was injected slowly during approximately 1 minute into the LAD cannula. Measurements of all variables were made before injection and at the time of the maximal coronary blood flow response (determined visually, usually by 60 seconds). If no changes in coronary flow were observed, measurements were recorded at 45-60 seconds after injection. Purified human C5a (three pigs), crude porcine C5a (two pigs), or purified porcine C5a (five pigs) was administered randomly in one of three doses including 10 ng, 100 ng, and 500 ng. Doses higher than 500 ng, and occasionally 500 ng, caused lowering of blood pressure. In these cases proximal aortic pressure was maintained constant by rapid infusion of donor pig blood or by partial constriction of the descending thoracic aorta. Pilot studies indicated that doses greater than 1 /ig caused severe arterial hypotension, pulmonary hypertension, and subsequent cardiac failure from which the animals generally did not recover. These responses were most likely to occur when coronary venous blood recirculated. Injections were given at least 15-30 minutes apart to minimize tachyphylaxis and only at a time when hemodynamic conditions were stable. Arterial and coronary venous blood samples were taken at the time of maximal coronary blood flow responses for subsequent measurements of gas content and complete blood counts.
If arterial blood pressure changed more than 10 mm Hg during an injection, the observation was not included. One animal that received crude porcine C5a showed no response at any dose and was not included. No qualitative differences between the effects of human, crude porcine, or purified porcine C5a were observed. Therefore, we combined results from the nine remaining animals.
In five cases, coronary venous blood was collected every 15 seconds after C5a injection. This permitted serial evaluation of venous leukocyte levels.
At the end of the study, the hearts of five animals were removed for histological evaluation. The LAD and LCX were cannulated individually and perfused with saline for 15 minutes in vitro according to physiological pressures to remove all blood components from freely flowing capillaries. Then, the regions were perfused with glutaraldehyde until the myocardium was firm. Transmural sections of tissue from the LAD and LCX regions were removed for fixation, staining, and histological analysis.
Samples of arterial and coronary venous blood were collected in EDTA tubes on ice at the times described above. Samples were mixed thoroughly and complete blood counts were read with a QBC centrifugal hematology system (Becton-Dickinson, Clay Adams, Franklin Lakes, New Jersey), which allowed granulocyte and lymphocyte/monocyte fractions to be separated. The principles of this system are based on staining the leukocytes and platelets with acridine orange. Samples were centrifuged in calibrated capillary tubes, allowing the buffy coat to layer as platelets, lymphocytes, monocytes, and granulocytes. A blue-violet light illuminated the sample in an automated reader, permitting an observer to align the cursor along the interfaces of the cell layers. Once aligned, the position of the cursor was automatically entered into the computer, which automatically computed the test values. This system has been tested extensively in our laboratory and has been found to agree within 10% of standard (Coulter) counting methods for hematocrit and leukocytes and within 20% for platelets. The observer was blinded to the identity of the samples. In addition, to avoid interobserver variation, one experienced observer was responsible for all measurements. Leukocyte counts are reported as 10 5 cells/ml.
Porcine C5a was prepared from zymosan-activated porcine serum as previously described by Gerard and Hugli.
8 Human C5a anaphylatoxin was isolated from zymosan-activated human serum containing 10 /xM 2-mercaptomethyI-3-gyamdmoethylthic>-propanoicacid (Calbiochem, La Jolla, California) as a carboxypeptidase inhibitor. 28 The purity and quantity of both polypeptides were established by amino acid analysis after acid hydrolysis. The solutions of C5a were formulated by diluting with 1% bovine serum albumin. This diluent also served as the vehicle control.
Tissue Histology
Tissue blocks were dehydrated in a graded series of alcohols and embedded in epoxy resin. A l-fimthick section from each block was stained with toluidine blue and analyzed by two observers in a blinded fashion using a light microscope equipped with a x 10 eye piece and x45 objective. All capillaries were counted; those containing erythrocytes or leukocytes were considered to be obstructed because they were not cleared during perfusion with the clear buffer solution. Conversely, capillaries that were clear were considered to be perfused.
In Vitro Studies
The direct effect of C5a on large coronary arteries was examined with an isolated perfused coronary artery preparation as previously described by Ogletree et al. 29 Segments of the LAD (1.5 cm length, 750-1,000 fim i.d., n = 11) were dissected from the hearts of six pigs that were not previously instrumented or treated. The proximal end of the vessel segment was cannulated with a 16-18-gauge Luer Stub adapter (Becton-Dickinson, Clay Adams, Parsippany, New Jersey). The cannula was secured with 3-0 silk, and the tissue surrounding the vessel was dissected carefully from the vessel. The arteries then were perfused with oxygenated (95% 0^-5% COJ Krebs-Henseleit buffer at 37° C. Each artery was placed in a 10-ml vial, and the buffer was circulated with a variable speed peristaltic pump (505-1200, Harvard Apparatus, South Natick, Massachusetts). Vessel perfusion pressure was maintained between 75 and 100 mm Hg (Gould P231D, Gould-Statham, Cleveland, Ohio) and recorded continuously (Mark 280, Gould-Brush, Cleveland, Ohio). After a 60-minute equilibration period, the vasoactive capacity of each segment was established by addition of 25-50 mM KC1 to the perfusate. 29 In this system, increases in vascular tone (vasoconstriction) during constant flow perfusion were recorded as increases in coronary perfusion pressure. After washout of potassium chloride and return of vascular tone to baseline, segments were tested for their responses to cumulative doses of C5a to achieve a final bath concentration of 10-500 ng/ml (1-50 nM). Purified porcine C5a was added to the perfusate of seven segments from four pigs. Four of these preparations then were tested for their responses to human C5a (10-1,000 ng/ml). In five vessel segments from two separate pigs, the buffer solution was replaced with whole blood from a donor pig. Responsiveness to porcine C5a was examined in four blood-perfused preparations, while the effect of human C5a was examined in one blood-perfused preparation. The effects of vehicle (1% serum bovine albumin) were tested in all preparations.
Data Analysis
In each animal, the dose of complement causing the greatest change in coronary blood flow was selected for comparison to the dose of vehicle. Data are presented as mean±SEM. The immediately preceding control and the maximal response periods were compared by paired Student's t test for the vehicle or C5a. Significant differences were assumed at p<0.05. In addition, dose-response curves were assessed for 10, 100, and 500 ng. Finally, the time course of the responses was evaluated in those animals in which serial measurements were made.
Results
Intracoronary injection of C5a significantly decreased coronary blood flow (Table 1, Figure 1) . In one animal, a 10-ng dose produced the maximal decrease in coronary blood flow; maximal responses were seen with injection of 100 ng in four animals and with 500 ng in four animals. Plasma concentrations of C5a were estimated by dividing the amount delivered (nanograms per minute) by coronary plasma flow (milliliters per minute); concentrations that produced maximal effects on coronary blood flow ranged from 3.5 to 116 ng/ml. The average concentration was 21 ±11 ng/ml. Table 1 and Figure 1 show the hemodynamic and metabolic effects observed during the maximal responses to C5a. Coronary blood flow significantly decreased, while the coronary vascular resistance significantly increased. Coronary venous oxygen content decreased, indicating an increased oxygen extraction across the myocardium. Arterial oxygen content remained constant. However, despite the increased extraction of oxygen, the drop in coronary blood flow was accompanied by a deterioration of myocardial function (segmental shortening) in the LAD region. 
FIGURE 1. Recordings of hemodynamic responses to 500 ng C5a injected into the proximal left anterior descending coronary artery (LAD). Letters with arrows at bottom of the figure indicate times at which regional coronary blood was sampled for measurement of leukocyte concentrations or blood gases.
We also observed an increase in the myocardial extraction of white blood cells in the LAD region (intravascular trapping). There was no significant extraction of platelets, erythrocytes, or lymphocytes during C5a injections. Thus, only granulocytes were trapped during administration of C5a. As demonstrated in Figure 1 , the effects of C5a at doses less than 1 fig were immediate, profound, and short-lived. Coronary blood flow had returned to baseline levels by 2 minutes. In this and all other cases, coronary blood flow decreased just before changes in regional myocardial function. A tendency for function of the posterior ventricle (LCX region) to increase was observed, although these increases were not significant (Table 1) .
No significant changes in mean aortic blood pressure, heart rate, left ventricular dP/dt, pulmonary arterial blood pressure, or regional LCX function were observed with the concentrations of C5a used in this study. Also, in contrast to those effects observed after C5a administration, intracoronary injection of vehicle produced no changes in any measured variable.
When responses to C5a were examined as a dose-response relation, a 40% decrease in coronary blood flow was reached at doses of 100 ng (top left, Figure 2 ). Accompanying these reductions in blood flow were dose-related increases in coronary vascular resistance (top right), decreases in regional function (bottom left), and increases in leukocyte trapping (bottom right). Although we noted that there was significant trapping of leukocytes with a dose of 10 ng, there were no significant changes in blood flow or coronary resistance. The doses of C5a used in these experiments did not alter arterial concentrations of leukocytes. However, when higher, repeated doses of C5a were given in pilot studies, systemic effects, including hypotension and leukocytopenia (granulocytopenia), were observed.
We also observed an additional, qualitative relation between leukocytes and coronary hemodynamics in three animals. In each of these animals after leukocyte depletion, the response to C5a was either absent or markedly reduced. In one animal with a systemic (arterial) leukocyte concentration of 2.6 x 10 6 cells/ml, a high dose (10 /ig) of C5a had no effect on coronary blood flow. In the second animal with an arterial concentration of 4.4 x 10 6 leukocytes/ml, the highest dose (1 fig) of Values are mean + SEM of number of capillaries from duplicate slides read from each region in each of five animals. Total filled capillaries include both erythrocyte and granulocyte filled vessels. Total capillaries counted includes total filled and nonfilled capillaries. No significant differences exist between the two regions.
LCX, left circumflex coronary artery; LAD, left anterior descending coronary artery.
very small increase in coronary vascular resistance was found (3.43-5.58 peripheral resistance units (PRU) upon injection of 500 ng C5a. When the response of this animal was compared with the response of the whole group of animals (Figure 2 ), the magnitude of this response was observed to be quite small. The level of leukocytes extracted at this time was low also, only 0.8 x 10 6 cells/ml (see Figure 2 for comparison to the whole group).
Serial blood samples were withdrawn to establish a time course for changes in coronary blood flow, coronary vascular resistance, segment function, and leukocyte trapping (Figure 3) . The initial event appeared to be an increased extraction of granulocytes, followed by a reduction in coronary blood flow and myocardial function. Flow remained low for 60 seconds, then rapidly returned to baseline flow, which was reestablished by 2 minutes. Finally, maximal trapping of granulocytes preceded the maximal decreases in coronary blood flow.
Histological data from treated (LAD) and nontreated (LCX) regions were available from five animals ( Table 2 ). Comparable numbers of total capillaries were counted in sections from each region (mean, 165 in LCX; 162 in LAD). Of the capillaries in the LAD region, an average of seven were filled with red blood cells, indicating an obstructed capillary downstream since all freely flowing capillaries are washed clear of cellular components during the saline perfusion and fixation. An average of two capillaries contained a granulocyte, while the remainder (153) were empty. No significant differences were observed between the LAD and LCX regions. When ratios of filled-to-total capillaries were calculated, the results confirmed that no differences in the microvasculature of the two regions existed and that capillary plugging did not persist after repeated injections of C5a.
In in vitro studies, all 11 LAD segments demonstrated vasoconstriction when challenged with potassium chloride. Increases in coronary perfusion pressure, indicating vasoconstriction, ranged from 10 to 70 mm Hg and averaged 25 ± 5 mm Hg (mean ± SEM). Porcine C5a in cumulative concentrations of 10-500 ng/ml did not alter the perfusion pressure ( -0.4 ± 0.6 mm Hg, « = 7). Also, human C5a (10-1,000 ng/ml) did not increase coronary perfusion pressure (0.6 ±1.2 mm Hg, n = 4). Similarly, addition of either porcine or human C5a did not cause changes in coronary perfusion pressure in five preparations perfused with whole blood (0.7 ±0.5 mm Hg). These data indicate that in large (750-1,000 /im) coronary vessels of pigs, C5a does not cause direct vasoconstriction during perfusion with either buffer alone or in the presence of whole blood.
Discussion
The major findings of this study are that intraarterial administration of the chemoattractant C5a caused significant reductions in coronary blood flow and local myocardial function. The reduced myocardial function suggests that ischemia occurred transiently. Reductions in flow and function were accompanied by significant increases in myocardial oxygen extraction, indicating an imbalance between oxygen supply and demand, despite normal perfusion pressures. The trapping of circulating granulocytes observed during complement administration is consistent with the hypothesis that granulocyte plugging in the microcirculation caused the reduction in regional blood flow and function.
Complement-induced aggregation and modulation of the adhesiveness of white blood cells has been established. 30 -33 These phenomena result from C5a binding to specific receptors that exist on neutrophils. Half-maximal receptor occupancy and biological responses have been observed at a final concentration of 1-10 nM. 30 The binding of C5a to the neutrophil is a rapid, saturable, and short-lived process since the peptide is internalized and catabolized. 3435 Neutrophil adherence to endothelium occurs within 2 minutes of stimulation by complement. 3034 The time courses of these phenomena were confirmed in the present in vivo study. For example, within 30 seconds of initiating the stimulus, maximal increases in granulocyte trapping within the coronary circulation were noted. We then observed a decrease in extraction of leukocytes (loss of the aggregating trapping effect), which was completed by 2 minutes. Thus, our findings in vivo are consistent with cellular mechanisms predicted by the above previous studies.
An important premise for the present study is that the complement cascade is activated by myocardial ischemia and that concentrations of C5a used in the present study are representative of those found during ischemia. Evidence of activation of complement comes from studies demonstrating that Clq and C3 are localized in the myocardium in regions of ischemia.
12324 Furthermore, polymorphonuclear leukocytes are collocalized with Clq, 23 suggesting that the activation of the complement pathway likely is responsible for leukocyte chemotaxis. However, the second part of the initial premise is harder to determine because C5a, once bound to neutrophils, is rapidly internalized and degraded to nonantigenic products. 36 Therefore, it is usually not possible to measure the C5a that has been produced. One recent study demonstrated that C5a increases from 8 to 30 ng/ml after administration of recombinant tissue plasminogen activator in patients with a complete coronary occlusion and myocardial ischemia. 37 These data suggest that C5a potentially could increase to the range used in the present study. It is also important to note that the k d of C5a for granulocyte receptors is 1 nM (10 ng/ml). 34 This is within the concentration range used in the present study, assuming that some dilution of C5a occurs after injection. Thus, we believe that myocardial ischemia activates the complement cascade and that C5a, in the concentration range used in this study, attracts neutrophils and induces their aggregation and adhesiveness.
Either human or porcine C5a was injected into the pig's coronary arteries in these experiments. Although these purified preparations contained only C5a, it is well recognized that C5a undergoes enzymatic degradation to des-Arg C5a in vivo. 38 Thus, either or both C5a or des-Arg C5a may have bound to receptors to cause the observed granulocyte and coronary hemodynamic effects.
Granulocyte-endothelial interactions have been shown to influence capillary flow and vascular resistance. Granulocytes are the cellular elements most likely to be associated with capillary plugging because of their size, stiffness, viscosity, and adhesion to vascular endothelium. 171820 In the absence of activation and during normal perfusion pressures, these cells contribute to the microvascular resistance due to slow entry and passage through capillaries. For example, in a skeletal muscle preparation with a buffer flow of 0.9 ml/min-100 g, infusion of 9x 10 6 leukocytes/100 g, which resulted in a circulating level of 9xlO 6 cells/ml, caused a 72% increase in precapillary resistance. 19 In the setting of myocardial ischemia and reperfusion, an incomplete return of blood flow has been observed. 13 In addition, granulocyte plugging of capillaries occurs in no-reflow capillaries after 1,3, or 5 hours of ischemia and reperfusion. 20 Finally, the capillary no-reflow phenomenon is prevented by granulocytopenia. 11 Such studies point to the capacity for granulocytes to significantly obstruct the coronary microcirculation. However, these previous studies do not prove that granulocytes can be activated in myocardium perfused by normal physiological pressures to cause trapping and subsequent significant hemodynamic and myocardial functional responses. In the present study, up to a 40% decrease in coronary blood flow was observed immediately after a significant trapping of leukocytes (4.2 x 10 6 cells/ml) in the local circulation. Upon washout of the cells, coronary blood flow and segment function rapidly returned to basal conditions. A histological postmortem examination of the complement-infused region did not show significant numbers of blocked capillaries or retained granulocytes. However, this is expected because granulocyte washout and restoration of coronary blood flow had occurred. Thus, the present results, supported by previously reported studies, are in keeping with the hypothesis that complement-activated granulocytes reduce coronary flow.
We observed that the coronary hemodynamic responses to C5a were blunted in three leukopenic animals. This provides additional in vivo evidence that white blood cells are important contributors to C5a-induced reduction in coronary flow and myocardial function.
The possibility exists that C5a alters vascular resistance by a direct vascular effect 7 -9 or by release of an intermediate metabolite such as one of the leukotrienes or thromboxane A 2 , of which both secondarily alter coronary vascular tone. Leukotriene C 4 and D 4 are produced and released from granulocytes. 39 These substances are potent vasoconstrictors of the coronary circulation of swine. 40 In addition, it has been demonstrated that thromboxane A 2 is produced in conjunction with complement activation in the lung. 41 Thromboxane A 2 can be produced by granulocytes. 42 Complement fragments des-Arg C5a and C5a have been shown to directly contract smooth muscle in guinea pig ileum 7 and blood vessels in certain organs. 9 Finally, C3a has been shown to constrict coronary arteries of isolated, perfused guinea pig hearts through leukotrieneand prostaglandin-mediated mechanisms. In our in vitro studies, we observed no effect of complement on large coronary vessels either in the presence or absence of formed blood elements and other components of whole blood. Thus, C5a does not directly constrict large coronary arteries of pigs. However, we cannot rule out direct action of C5a upon smaller resistance arteries or leukotriene-and thromboxaneinduced vasoconstriction of small coronary arteries that would contribute to the decreased coronary blood flow observed in our study. We did not observe an increase in heart rate as was seen with C3a in guinea pig hearts, 25 presumably because C5a did not have direct access to the sinoatrial node.
In summary, we have shown that, in normal myocardium, the administration of a potent chemoattractant (C5a) reduced coronary blood flow sufficiently to produce myocardial ischemia. The reduction in blood flow was associated closely with the trapping of granulocytes in the microcirculation, which is consistent with the known time course of the cellular effects of C5a. We observed that the duration of the effect of C5a was short (less than 2 minutes), at which time granulocytes no longer were trapped and blood flow and local myocardial function were restored to normal. These findings implicate activated granulocytes as effectors of reduced coronary flow and myocardial function during normal perfusion pressures. These observations may be of clinical significance for patients experiencing myocardial ischemia or undergoing cardiopulmonary bypass, which are situations reported to be associated with endogenous complement activation. 1 -2343 
